OneSource Specialty Pharma has raised its FY28 revenue forecast from $400 million to over $500 million, driven by strong ...

In a growing trend, some users of GLP-1 medications are hailing their results with microdosing, taking ...

While society's obsession with female bodies is nothing new, a wave of celebrities who embraced their larger bodies are ...

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price through TrumpRx.

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

CEO Siddharth Mittal believes Biocon’s existing portfolio, including liraglutide, gives it an edge in a highly competitive ...

Something profound is happening in Canada’s food economy, and most people haven’t quite grasped it yet. It’s not a new grocer ...

Obesity isn’t a moral failing; it’s what happens when humans evolved for scarcity encounter permanent abundance. When you take a trip on a cruise ship with unlimited buffets, you gain weight — not ...

From skin cancer awareness for veterans to groundbreaking research and rising infectious disease concerns, here's your health ...

Sandoz CEO Richard Saynor predicts biosimilars referencing semaglutide to enter the Canadian market in early in 2026, as the patent protection for Novo Nordisk’s blockbuster drug looms.

How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American Association for the Study of Liver Disease’s (AASLD) 76 ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.